···
← delfee

Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump

clinical_trial_failureGlobalInvestor's Business Daily9 Jul, 20:26 UTC
Result1/1 correct

Context

Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump  Investor's Business Daily AstraZeneca shares down as drug trial fails to meet target  The Times Crude oil prices rise again while UK stock market falls, dragged down by AstraZeneca – as it happened  The Guardian FTSE 350 shares round-up: AstraZeneca, BAT, Playtech, Saga  Interactive Investor Major drugmaker loses $27 billion in market value after failed trial  MarketWatch

What it means

A failed clinical trial at AstraZeneca has historically been associated with a sharp, immediate drop in the company's own shares as investors reprice its pipeline value — in this case erasing roughly $27 billion in market cap. Rival drugmakers with competing or complementary drug candidates, like Pfizer, have historically seen sympathy gains as competitive dynamics shift in their favor. AstraZeneca's large weighting in the FTSE 100 also dragged the broader UK equity index modestly lower. (Lower-conviction channels were filtered out by our selectivity bar.)

Causal chain

How to read a signal
Severity
the event's market impact, 1–5
Direction
/ likely price move for the asset
Exp. move
the size of the abnormal move we'd expect if the call plays out — not a claim a move will happen:
Ssmall<1%
Mmoderate1–5%
Llarge>5%
Most flagged events don't move beyond noise; those count against us (see the track record).
Timeframe
the window we measure over:
1dshort
5dmedium
21dlong
Conviction
how well-established the directional call is (textbook → speculative) — not a guaranteed outcome:
low
average
strong

Get the next signal the moment it breaks.

The full live feed, asset filters, and alerts — free.

Sign up free →

Not investment advice · for informational purposes only. Generated 10 Jul, 12:20 UTC